Human Microbiome Market Worth $658 Million by 2023

DALLAS, September 10, 2014 /PRNewswire/ --

According to the new market research report"Human Microbiome Marketby Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & byProduct (Probiotic, Prebiotic, Food, Medical Food,OtherSupplements, Device, Drug) -Global Forecast to 2023",published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Human Microbiome Market along with the estimates and forecasts of the revenue and share analysis.

Browse 40 market data tables and 61 figures spread through 150 Pages and in-depth TOC on"Human Microbiome Market"

http://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

Early buyers will receive 10% customization on this report.

The Human Microbiome Market is expected to reach $658 Million by 2023 from $294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023).

The Human Microbiome Market is segmented on the basis of application, disease, product, and geography. On the basis of application, the market is further segmented into therapeutics and diagnostics. Therapeutics is expected to account for the largest market share in the Human Microbiome Market 2019 onwards. Factors such as rising incidences of lifestyle diseases, increasing aging population, and technological developments such as microbiome sequencing drive the growth of the Human Microbiome Market. On the basis of disease, the Human Microbiome Market comprises of obesity, diabetes, autoimmune disorder, acute diarrhea, cancer, mental disorder, and others. Among these, the acute diarrhea segment is expected to account for the largest share and will be the fastest-growing segment in 2019, followed by obesity.

On the basis of product, the Human Microbiome Market is segmented into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Probiotics is expected to account for the largest market share and will also register a growth rate of 25.2% in the forecasted period of 2019 to 2023. These probiotics helps in maintaining the gut flora and they has been emerging as a useful tool in alleviating symptoms of chronic disorder.

Further Inquiry:http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=37621904

Europe is expected to account for the highest share in 2019 and is poised to grow at a double-digit CAGR. This growth can be attributed to the rising incidences of lifestyle diseases, diarrheal infections, and autoimmune disorders that are further adding to the overall prevalence of chronic diseases. Asia is expected to be the second largest-growing region of the Human Microbiome Market in 2019. The high population base and improved purchasing power of patients are the major drivers of this market. Moreover, economic instability in the western countries enables companies to focus on the Asian region in order to meet their revenue targets.

However, growth of the North American region is expected to be slow in the forecast period due to the limited awareness regarding the beneficial use of microbiome-based products.

The key players in the Human Microbiome Market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel (U.S.), and Merck (U.S.).

Browse related reports

Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019

http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, healthcare IT semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: [phone]
Email: [e-mail]

Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology